In summary, we determined that the combination of gilteritinib plus CUDC-907 potently induces apoptosis in both FLT3-ITD AML cell lines and primary patient samples, and significantly prolonged survival of NSGS mice bearing systemic MV4-11 leukemia. Here, FLT3 is linked to acute myeloid leukemia.